Argenx Se: Strategic Focus and Growth Potential in Graves’ Disease Treatment Justifies Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Argenx Se with a price target of $915.00. Despite the discontinuation of the TED program, Argenx remains committed to its Vision 2030 plan, aiming to develop five new molecules in Phase 3 and treat 50,000 patients by 2030. The company's strategic focus on FcRn therapy for Graves’ Disease and prudent management support the Buy rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments